Atlas Trials

Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

Clinical trial NCT04848974 · COMPLETED

Trial details

NCT number
NCT04848974
Sponsor
M.D. Anderson Cancer Center
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Secondary Acute Myeloid Leukemia
Start date
2021-06-11
Primary completion
2024-10-30
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.